Regulatory Challenges Hospira has experienced recent quality assurance issues leading to the closure of manufacturing facilities and recalls of products like vancomycin and propofol. This indicates a need for advanced quality management systems, supplier validation solutions, and regulatory compliance services.

Innovative Biosimilars The company launched biosimilar versions of infliximab, demonstrating a focus on developing and commercializing cost-effective biologic therapies. Opportunities exist to provide biosimilar manufacturing support, R&D collaboration, or market entry consulting.

Sustainability Initiatives Hospira has introduced PVC/DEHP-free IV bags, emphasizing a commitment to reducing plastic waste and enhancing patient safety. Solutions around eco-friendly manufacturing materials and sustainable packaging could align well with their growth strategy.

Recent Market Focus The company's strategic updates around new product launches and partnerships with medical device firms highlight ongoing expansion in infusion technology and medical device categories. Sales efforts could target device safety solutions and integrated healthcare technology offerings.

Acquisition and Integration As part of Pfizer, Hospira benefits from extensive resources and distribution networks, providing broad market access. Collaboration opportunities may include leveraging Pfizer’s infrastructure for new product introductions or expanding into emerging markets.